Your fact-checks will appear here
Monoclonal antibody against β-amyloid
No reliable information about a therapy called "memo blast" is present in the supplied reporting, so its effects cannot be judged from these sources; the documents instead evaluate anti-amyloid monocl...
New disease‑modifying monoclonal antibodies for early Alzheimer’s—lecanemab (Leqembi) and donanemab (Kisunla)—are expensive at scale (Leqembi cited at $26,500/year; Kisunla initial pricing described a...
Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...
The core factual findings are simple: Leqembi (lecanemab) received and was , after a confirmatory trial demonstrated clinical benefit . Aduhelm (aducanumab) received , and public records in the datase...
Dr. Sanjay Gupta’s recent reporting emphasizes lifestyle interventions and newer antibody drugs like Leqembi (lecanemab) as reasons for renewed hope, noting Leqembi clears amyloid plaques and slowed c...
Available sources do not report that a company or product named “Neurocept” ran clinical trials using amyloid PET, tau imaging, or CSF biomarkers as primary endpoints; the search returns consumer supp...
Neurocept’s primary endpoints are not mentioned in the supplied search results; available sources instead describe how aducanumab’s approval relied on a surrogate biomarker (amyloid reduction) while l...
Neurocept’s phase 3 data are not described in the provided sources; available material lists trial completion calendars and company financial reports but does not report Neurocept’s phase 3 primary en...
Available sources do not mention a product named “Neurocept,” any advisory committee vote on it, or reasons members voted for or against it; searches of FDA advisory committee pages, meeting rosters a...
The analyses provided indicate that the FDA primarily uses the pathway to approve some Alzheimer’s therapies based on surrogate biomarkers such as amyloid-beta reduction, a process that has generated ...